Cambridge, UK-based biotechnology company acquired by Insmed in 2023
Cambridge, UK-based biotechnology company acquired by Insmed in 2023. Its synthetic rescue platform uses whole-genome assays and human genetics to identify functionally connected genes and drug targets that may counteract disease-causing mutations in genetically defined diseases. The platform supports discovery across small molecules, oligonucleotides, and gene therapies.